➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
McKinsey
AstraZeneca
Express Scripts
Merck

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LURBINECTEDIN

« Back to Dashboard

All Clinical Trials for Lurbinectedin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01314599 Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome Completed PharmaMar Phase 1 2011-05-01 Phase I Study of PM01183 in Patients with Advanced Acute Leukemia to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183.
NCT01831089 Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors Completed PharmaMar Phase 1 2013-09-01 Clinical trial of PM01183 in combination with paclitaxel, with or without bevacizumab, in patients with solid tumors
NCT01951157 A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients Completed PharmaMar Phase 2 2013-10-01 A clinical study of lurbinectedin(PM01183) alone or in combination with gemcitabine in comparison to docetaxel for the treatment of unresectable non-small cell lung cancer (NSCLC)patients
NCT01980667 Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors Recruiting PharmaMar Phase 1 2014-02-01 Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Cisplatin in Patients with Advanced Solid Tumors to determine the recommended dose (RD) of PM01183 in combination with cisplatin, to characterize the safety profile, the pharmacokinetics (PK) of this combination, to obtain preliminary information on the clinical antitumor activity and to conduct an exploratory pharmacogenomic (PGx) analysis.
NCT02210364 Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC). Completed PharmaMar Phase 1 2013-04-01 Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Capecitabine in Patients with Unresectable Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC) to determine the recommended dose (RD) of PM01183 in combination with capecitabine, to characterize the safety profile, to explore the feasibility of PM01183 dose optimization, to characterize the pharmacokinetics (PK), to obtain preliminary information on the clinical antitumor activity of this combination and to conduct an exploratory pharmacogenomic (PGx) analysis.
NCT02421588 Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients Recruiting PharmaMar Phase 3 2015-05-01 Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate the activity and safety of PM01183 versus PLD or topotecan as control arm in patients with platinum-resistant ovarian cancer. PM01183 will be explored as single agent in the experimental arm (Arm A) versus PLD or topotecan in the control arm (Arm B).
NCT02448537 A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas Active, not recruiting Dana-Farber Cancer Institute Phase 2 2015-08-01 This research study is investigating a drug called PM01183 alone and in combination with chemotherapy drugs called gemcitabine or doxorubicin as a possible treatment for metastatic or unresectable Sarcoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lurbinectedin

Condition Name

Condition Name for Lurbinectedin
Intervention Trials
Ovarian Cancer 2
Advanced Solid Tumor 2
Small-cell Lung Cancer 2
Advanced Solid Tumors 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lurbinectedin
Intervention Trials
Small Cell Lung Carcinoma 4
Lung Neoplasms 4
Carcinoma, Non-Small-Cell Lung 2
Preleukemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lurbinectedin

Trials by Country

Trials by Country for Lurbinectedin
Location Trials
United States 45
Switzerland 3
Spain 2
Belgium 1
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lurbinectedin
Location Trials
Texas 5
California 4
New York 3
Massachusetts 3
Arizona 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lurbinectedin

Clinical Trial Phase

Clinical Trial Phase for Lurbinectedin
Clinical Trial Phase Trials
Phase 3 2
Phase 2 4
Phase 1/Phase 2 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lurbinectedin
Clinical Trial Phase Trials
Recruiting 6
Completed 5
Not yet recruiting 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lurbinectedin

Sponsor Name

Sponsor Name for Lurbinectedin
Sponsor Trials
PharmaMar 12
Luye Pharma Group Ltd. 1
Massachusetts General Hospital 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lurbinectedin
Sponsor Trials
Industry 15
Other 6
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
McKinsey
Moodys
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.